ClinicalTrials.gg
CompletedNCT04201093TEMPO-1Updated Jul 28, 2025Results posted

Fixed-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3 interventional study of Tavapadon and Placebo in Parkinson Disease, sponsored by AbbVie. Completed at 77 sites in 12 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
529
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
2nd of 11
529 · median 57
Started
2019
the only one that year
Phase 3
4 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
4 of 11
AbbVie

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 5th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinsonian Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Movement Disorders
  • Neurodegenerative Diseases
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male and female participants aged 40 to 80 years, inclusive, at the time of signing the form (ICF)
  • Sexually active men or women of must agree to use acceptable (at minimum) or highly effective , or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment
  • Participants who are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
  • Participants with a diagnosis of PD that is consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria
  • Participants with modified Hoehn and Yahr stage 1, 1.5, or 2
  • Participants with disease duration (from time of diagnosis) of less than (\<) 3 years and disease progression in the 3 years before signing the ICF
  • Participants with an MDS-UPDRS Part II score >=2 and Part III score >=10 at the Screening Visit and at the Baseline Visit
  • Participants with early PD who, in the opinion of the investigator, require pharmacologic intervention for disease management
  • Participants who are treatment naïve or have a history of prior incidental treatment with dopaminergic agents (including Levodopa [L-Dopa] and dopamine receptor agonist medications) for \<3 months in total but not within 2 months of the Baseline Visit. Prior and concurrent use of monoamine oxidase B (MAO-B) inhibitors is permitted if use was initiated >90 days before the Baseline Visit and the dosage will remain stable for the duration of the trial (i.e, no change in the MAO-B inhibitor dose is permitted during the trial)
  • Participants who are willing and able to refrain from any PD medications that are not permitted by the protocol (including dopaminergic agents) throughout participation in the trial.

Key Exclusion Criteria:

  • Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supra nuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or post stroke parkinsonism).
  • Participants with a history of nonresponse or insufficient response to L-Dopa at therapeutic dosages.
  • Participants with a history or current diagnosis of a impulse control disorder (Disruptive, Impulse Control, and Conduct Disorder per ).
  • Participants with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures.
  • Participants with a history of psychosis or hallucinations within the previous 12 months.
  • Participants who answer "yes" on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
  • Participants with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180 days)
  • Participants with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the participant from understanding the ICF or participating in the trial
  • Participants with any condition that could possibly affect drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).
  • Participants who have a positive result for (HIV) antibodies, surface antigen (HbsAg), or virus (HCV) antibodies at screening.
  • Participants with a history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical intervention; second- or third-degree atrioventricular block; sick sinus syndrome; severe or unstable angina; or congestive heart failure within the last 12 months. A recent (less than or equal to [\<=] 12 months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control.
  • Participants with a history of neuroleptic malignant syndrome.
  • Participants who are currently receiving moderate or strong inducers or CYP3A4 inhibitors (except for topical administration).
  • Participants with a positive urine drug screen for illicit drugs are excluded and may not be retested or rescreened. Participants with a positive urine drug screen resulting from use of marijuana (any Tetrahydrocannabinol [THC]-containing product), prescription, or over-the-counter medications or products that, in the investigator's documented opinion, do not signal a clinical condition that would impact the safety of the participant or interpretation of the trial results may continue evaluation for the trial following consultation and approval by the medical monitor
  • Participants with a (MoCA) score \<26
  • Participants with clinically significant orthostatic hypotension (eg, syncope)
  • Participants with a 12-lead demonstrating a interval >450 msec
  • Participants with moderate or severe renal impairment ( as estimated by Cockcroft-Gault formula \<30 mL/min or on dialysis)
  • Participants with any of the following abnormalities in clinical laboratory tests at the Screening Visit, as assessed by the central laboratory and confirmed by a single repeat measurement, if deemed necessary:

    • (AST) or Alanine Aminotransferase (ALT) >=3 × Upper Limit Normal ().
    • Total >=1.5 × ULN. Participants with a history of Gilbert's syndrome may be eligible provided they have a value \<ULN for direct bilirubin.
  • Participants with other abnormal laboratory test results, vital sign results, or ECG findings unless, in the judgment of the investigator, the findings are not medically significant and would not impact the safety of the participants or the interpretation of the trial results.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
529 participants (actual)

Study arms

  • Experimental
    Tavapadon 5 mg

    Participants will receive tavapadon tablet titrated up to 5 milligram (mg) once daily (QD) orally for 27 weeks.

    Drug: Tavapadon

  • Experimental
    Tavapadon 15 mg

    Participants will receive tavapadon tablet titrated up to 15 milligram (mg) QD orally for 27 weeks.

    Drug: Tavapadon

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.

    Drug: Placebo

Interventions

  • Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.

    Also known as: PF-06649751, CVL-751

  • DrugPlacebo

    Participants will receive placebo matching to tavapadon QD orally for 27 weeks.

  • Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.

    Also known as: PF-06649751, CVL-751

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the MDS-UPDRS Parts II and III Combined Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

    Time frame: Week 26

Secondary outcomes

  1. Change From Baseline in the MDS-UPDRS Part II Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

    Time frame: Week 26

  2. Percentage of Responders With a Score of "Much Improved" or "Very Much Improved" on PGIC

    The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

    Time frame: Week 26

  3. Change From Baseline in the MDS-UPDRS Parts II and III Combined Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  4. Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  5. Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  6. Change From Baseline in the CGI-S Score

    The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants). Higher values represent a worse outcome.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  7. Change From Baseline in the CGI-I Score

    The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  8. Change From Baseline in the PGIC Score

    The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  9. Change From Baseline in the Epworth Sleepiness Scale (ESS)

    The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome.

    Time frame: Week 26

  10. Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)

    QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson's disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms.

    Time frame: Week 26

  11. Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.

    Time frame: Week 27

  12. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 190 days following last dose of study drug.

07

Results

Posted Jul 28, 2025

Participant flow

In this Phase 3, Double-Blind study, a total of 529 subjects with Parkinson's Disease (PD) were randomized in a 1:1:1 ratio to 3 treatment groups: Tavapadon 5 mg, Tavapadon 15 mg, or Placebo once daily (QD) for 27 Weeks.

Participant flow — Overall Study
MilestonePlaceboTavapadon 5 mgTavapadon 15 mg
Started175177177
Completed148134118
Not completed274359
Withdrew: Adverse event62935
Withdrew: Death210
Withdrew: Lack of efficacy512
Withdrew: Lost to follow-up001
Withdrew: Failure to meet continuation criteria001
Withdrew: Treatment with prohibited concomitant medications001
Withdrew: Non-compliance with study schedule001
Withdrew: Physician decision100
Withdrew: Protocol deviation100
Withdrew: Site terminated by sponsor531
Withdrew: Withdrawal by subject7815
Withdrew: Other012

Outcome measures

PrimaryChange From Baseline in the MDS-UPDRS Parts II and III Combined Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Parts II and III Combined Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Change From Baseline in the MDS-UPDRS Parts II and III Combined Score1.8 ± 0.82-9.7 ± 0.86-10.2 ± 0.88
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -11.5 · 95% CI -13.8 to -9.2
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -12.1 · 95% CI -14.4 to -9.8
SecondaryChange From Baseline in the MDS-UPDRS Part II Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Part II Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Change From Baseline in the MDS-UPDRS Part II Score0.9 ± 0.30-1.6 ± 0.31-1.7 ± 0.32
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -2.5 · 95% CI -3.3 to -1.7
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -2.6 · 95% CI -3.4 to -1.7
SecondaryPercentage of Responders With a Score of "Much Improved" or "Very Much Improved" on PGIC

The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Responders With a Score of "Much Improved" or "Very Much Improved" on PGIC
ParticipantsPlaceboTavapadon 5 mgTavapadon 15 mg
Percentage of Responders With a Score of "Much Improved" or "Very Much Improved" on PGIC186052
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed Models Analysis · p = <0.0001 · Odds ratio (or): 6.148 · 95% CI 3.339 to 11.321
  • Placebo vs Tavapadon 15 mg · Mixed Models Analysis · p = <0.0001 · Odds ratio (or): 5.968 · 95% CI 3.220 to 11.062
SecondaryChange From Baseline in the MDS-UPDRS Parts II and III Combined Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Parts II and III Combined Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Week 5-1.2 ± 0.57-4.4 ± 0.59-4.7 ± 0.59
Week 8-2.2 ± 0.62-6.9 ± 0.65-6.7 ± 0.65
Week 11-0.9 ± 0.72-8.1 ± 0.75-9.1 ± 0.75
Week 14-1.2 ± 0.74-8.8 ± 0.78-9.4 ± 0.78
Week 180.4 ± 0.78-9.1 ± 0.82-9.7 ± 0.83
Week 220.4 ± 0.81-9.6 ± 0.84-10.9 ± 0.86
Week 261.8 ± 0.82-9.7 ± 0.86-10.2 ± 0.88
Week 272.2 ± 0.92-8.6 ± 0.96-10.0 ± 0.99
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -11.5 · 95% CI -13.8 to -9.2
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -12.1 · 95% CI -14.4 to -9.8
SecondaryChange From Baseline in the MDS-UPDRS Parts I, II and III Combined Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Week 5-1.2 ± 0.67-3.9 ± 0.69-4.0 ± 0.69
Week 8-2.6 ± 0.72-6.4 ± 0.76-6.2 ± 0.75
Week 11-1.2 ± 0.81-7.7 ± 0.86-8.6 ± 0.86
Week 14-1.5 ± 0.85-8.8 ± 0.89-8.7 ± 0.90
Week 180.3 ± 0.91-9.3 ± 0.95-9.1 ± 0.96
Week 220.2 ± 0.94-9.5 ± 0.98-10.3 ± 1.00
Week 262.3 ± 0.95-9.4 ± 1.00-9.7 ± 1.02
Week 272.4 ± 1.06-8.5 ± 1.11-9.4 ± 1.14
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -11.7 · 95% CI -14.4 to -9.1
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -12.0 · 95% CI -14.7 to -9.3
SecondaryChange From Baseline in the MDS-UPDRS Parts I, II and III Individual Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Part I: Week 50.0 ± 0.230.6 ± 0.240.7 ± 0.24
Part I: Week 8-0.4 ± 0.230.5 ± 0.240.4 ± 0.24
Part I: Week 11-0.3 ± 0.230.4 ± 0.240.4 ± 0.25
Part I: Week 14-0.2 ± 0.250.0 ± 0.270.6 ± 0.27
Part I: Week 18-0.1 ± 0.25-0.2 ± 0.260.5 ± 0.27
Part I: Week 22-0.2 ± 0.260.2 ± 0.270.4 ± 0.28
Part I: Week 260.5 ± 0.270.2 ± 0.280.4 ± 0.29
Part I: Week 270.2 ± 0.270.2 ± 0.280.3 ± 0.29
Part II: Week 5-0.2 ± 0.22-0.8 ± 0.23-1.0 ± 0.22
Part II: Week 8-0.5 ± 0.23-1.0 ± 0.25-1.6 ± 0.24
Part II: Week 110.0 ± 0.26-1.7 ± 0.27-2.0 ± 0.27
Part II: Week 14-0.1 ± 0.27-1.6 ± 0.28-2.0 ± 0.28
Part II: Week 180.4 ± 0.29-1.9 ± 0.31-1.8 ± 0.31
Part II: Week 220.3 ± 0.28-1.7 ± 0.29-2.1 ± 0.29
Part II: Week 260.9 ± 0.30-1.6 ± 0.31-1.7 ± 0.32
Part II: Week 270.9 ± 0.31-1.7 ± 0.32-1.8 ± 0.33
Part III: Week 5-1.0 ± 0.44-3.7 ± 0.46-3.7 ± 0.45
Part III: Week 8-1.7 ± 0.50-6.0 ± 0.52-5.1 ± 0.52
Part III: Week 11-1.0 ± 0.55-6.5 ± 0.58-7.1 ± 0.59
Part III: Week 14-1.1 ± 0.58-7.2 ± 0.61-7.4 ± 0.61
Part III: Week 180.0 ± 0.60-7.3 ± 0.63-7.9 ± 0.64
Part III: Week 220.0 ± 0.64-8.0 ± 0.67-8.8 ± 0.68
Part III: Week 260.9 ± 0.63-8.1 ± 0.66-8.5 ± 0.68
Part III: Week 271.1 ± 0.71-7.1 ± 0.75-8.3 ± 0.77
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = 0.4822 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.3 · 95% CI -1.0 to 0.5
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = 0.7742 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.1 · 95% CI -0.9 to 0.6
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -2.5 · 95% CI -3.3 to -1.7
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -2.6 · 95% CI -3.4 to -1.7
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -9.0 · 95% CI -10.8 to -7.3
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -9.4 · 95% CI -11.2 to -7.6
SecondaryChange From Baseline in the CGI-S Score

The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants). Higher values represent a worse outcome.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the CGI-S Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Week 50.0 ± 0.04-0.1 ± 0.050.0 ± 0.05
Week 80.0 ± 0.05-0.1 ± 0.05-0.1 ± 0.05
Week 110.0 ± 0.05-0.2 ± 0.05-0.3 ± 0.05
Week 140.1 ± 0.05-0.2 ± 0.05-0.3 ± 0.05
Week 180.1 ± 0.05-0.3 ± 0.06-0.3 ± 0.06
Week 220.1 ± 0.05-0.2 ± 0.06-0.3 ± 0.06
Week 260.2 ± 0.05-0.3 ± 0.05-0.2 ± 0.06
Week 270.1 ± 0.05-0.2 ± 0.06-0.2 ± 0.06
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.5 · 95% CI -0.6 to -0.3
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.4 · 95% CI -0.5 to -0.2
SecondaryChange From Baseline in the CGI-I Score

The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the CGI-I Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Week 53.8 ± 0.063.4 ± 0.063.4 ± 0.06
Week 83.8 ± 0.063.2 ± 0.073.3 ± 0.07
Week 113.8 ± 0.073.0 ± 0.083.1 ± 0.08
Week 143.8 ± 0.073.0 ± 0.083.0 ± 0.08
Week 183.9 ± 0.082.8 ± 0.082.9 ± 0.08
Week 223.9 ± 0.082.9 ± 0.093.0 ± 0.09
Week 263.9 ± 0.092.8 ± 0.093.0 ± 0.09
Week 274.0 ± 0.092.8 ± 0.092.9 ± 0.09
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.1 · 95% CI -1.4 to -0.9
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.0 · 95% CI -1.2 to -0.7
SecondaryChange From Baseline in the PGIC Score

The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the PGIC Score
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Week 53.7 ± 0.073.5 ± 0.073.4 ± 0.07
Week 83.8 ± 0.083.2 ± 0.083.2 ± 0.08
Week 113.8 ± 0.083.0 ± 0.083.1 ± 0.08
Week 143.8 ± 0.082.8 ± 0.093.0 ± 0.09
Week 183.9 ± 0.092.8 ± 0.102.9 ± 0.10
Week 223.8 ± 0.092.9 ± 0.102.9 ± 0.10
Week 264.0 ± 0.102.8 ± 0.102.8 ± 0.11
Week 274.0 ± 0.102.8 ± 0.112.9 ± 0.11
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.2 · 95% CI -1.4 to -0.9
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.2 · 95% CI -1.5 to -0.9
SecondaryChange From Baseline in the Epworth Sleepiness Scale (ESS)

The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Epworth Sleepiness Scale (ESS)
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Change From Baseline in the Epworth Sleepiness Scale (ESS)-0.2 ± 0.23-0.3 ± 0.24-0.5 ± 0.24
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = 0.6047 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.2 · 95% CI -0.8 to 0.5
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = 0.2570 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.4 · 95% CI -1.0 to 0.3
SecondaryChange From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)

QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson's disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)
score on a scalePlaceboTavapadon 5 mgTavapadon 15 mg
Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)-2.1 ± 0.46-2.2 ± 0.47-2.4 ± 0.48
Statistical analysis
  • Placebo vs Tavapadon 5 mg · Mixed-effect Model Repeated Measurement · p = 0.8516 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.1 · 95% CI -1.4 to 1.1
  • Placebo vs Tavapadon 15 mg · Mixed-effect Model Repeated Measurement · p = 0.6421 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.3 · 95% CI -1.6 to 1.0
SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.

Time frame:
Week 27
Reported as:
Count of participants · Participants
Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPlaceboTavapadon 5 mgTavapadon 15 mg
Participants With Any Suicidal Ideations333
Participants With Any Suicidal Behaviors000
Participants With Any Suicidal Behaviors or Ideations333
Participants With Non-Suicidal Self-Injurious Behavior000
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 190 days following last dose of study drug.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlaceboTavapadon 5 mgTavapadon 15 mg
Number of Participants With Treatment Emergent Adverse Events (TEAEs)100142139

Adverse events

Collected over All-cause mortality was reported from enrollment until 4 weeks after the last dose of study drug. Treatment-emergent adverse events and serious adverse events were collected from the first dose of study drug until 4 weeks after the dose of study drug for all Arms. Mean duration on study drug was 27 weeks. Median time on study was 190, 190, 189 days for Placebo, Tavapadon 5 mg, and Tavapadon 15 mg, respectively.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/175 (1.1%)11/175 (6.3%)72/175 (41.1%)
Tavapadon 5mg QD1/177 (0.6%)4/177 (2.3%)125/177 (70.6%)
Tavapadon 15mg QD0/177 (0%)10/177 (5.6%)125/177 (70.6%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlaceboTavapadon 5mg QDTavapadon 15mg QD
COVID-19Infections and infestations3/1750/1770/177
COVID-19 PNEUMONIAInfections and infestations2/1750/1770/177
PNEUMONIAInfections and infestations1/1750/1772/177
ATRIAL FIBRILLATIONCardiac disorders1/1750/1770/177
INGUINAL HERNIAGastrointestinal disorders1/1750/1770/177
FALLInjury, poisoning and procedural complications1/1750/1770/177
FEMUR FRACTUREInjury, poisoning and procedural complications1/1750/1770/177
HEAD INJURYInjury, poisoning and procedural complications1/1750/1770/177
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1750/1770/177
PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1750/1770/177
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlaceboTavapadon 5mg QDTavapadon 15mg QD
NAUSEAGastrointestinal disorders3/17542/17748/177
HEADACHENervous system disorders9/17522/17737/177
DIZZINESSNervous system disorders8/17524/17721/177
FATIGUEGeneral disorders6/17510/17716/177
DYSGEUSIANervous system disorders0/17514/17714/177
VOMITINGGastrointestinal disorders1/17512/1779/177
DRY MOUTHGastrointestinal disorders0/17511/1779/177
ORTHOSTATIC HYPOTENSIONVascular disorders0/17511/1774/177
DYSPEPSIAGastrointestinal disorders2/1755/17710/177
ABNORMAL DREAMSPsychiatric disorders1/17510/1776/177

Baseline characteristics

Includes all enrolled subjects that received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboTavapadon 5 mgTavapadon 15 mgTotal
Mean63.5 ± 9.6263.7 ± 9.8063.8 ± 9.4063.7 ± 9.59
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTavapadon 5 mgTavapadon 15 mgTotal
Female636658187
Male112111119342
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTavapadon 5 mgTavapadon 15 mgTotal
Hispanic or Latino9131032
Not Hispanic or Latino154153158465
Unknown or Not Reported1211932
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTavapadon 5 mgTavapadon 15 mgTotal
American Indian or Alaska Native1001
Asian1012
Native Hawaiian or Other Pacific Islander0101
Black or African American3025
White168174172514
More than one race0101
Unknown or Not Reported2125
MDS-UPDRS Score at Baseline (Parts II and III Combined)
MDS-UPDRS Score at Baseline (Parts II and III Combined)(units on a scale)PlaceboTavapadon 5 mgTavapadon 15 mgTotal
Mean32.0 ± 9.9631.3 ± 10.8732.1 ± 11.5531.8 ± 10.80
08

Study locations

77 sites
  • Birmingham, Alabama
    Birmingham, Alabama 35233, United States
  • Little Rock, Arkansas
    Little Rock, Arkansas 72205, United States
  • Fountain Valley, California
    Fountain Valley, California 92708, United States
  • Los Angeles, California
    Los Angeles, California 90048, United States
  • Pasadena, California
    Pasadena, California 91105, United States
  • Englewood, Colorado
    Englewood, Colorado 80113, United States
  • Adventura, Florida
    Adventura, Florida 33180, United States
  • Boca Raton, Florida
    Boca Raton, Florida 33486, United States
  • Tampa, Florida
    Tampa, Florida 33613, United States
  • Augusta, Georgia
    Augusta, Georgia 30912, United States
  • Savannah, Georgia
    Savannah, Georgia 31406, United States
  • Chicago, Illinois
    Chicago, Illinois 60612, United States
  • Kansas City, Kansas
    Kansas City, Kansas 66160, United States
  • Scarborough, Maine
    Scarborough, Maine 04074, United States
  • Boston, Massachusetts
    Boston, Massachusetts 02215, United States
  • East Lansing, Michigan
    East Lansing, Michigan 48824, United States
  • Las Vegas, Nevada
    Las Vegas, Nevada 89106, United States
  • Asheville, North Carolina
    Asheville, North Carolina 28806, United States
  • Durham, North Carolina
    Durham, North Carolina 27705, United States
  • Columbus, Ohio
    Columbus, Ohio 43221, United States
  • Toledo, Ohio
    Toledo, Ohio 43614, United States
  • Philadelphia, Pennsylvania
    Philadelphia, Pennsylvania 19107, United States
  • Georgetown, Texas
    Georgetown, Texas 78628, United States
  • Houston, Texas
    Houston, Texas 77030, United States
  • Lubbock, Texas
    Lubbock, Texas 79410, United States
  • Burlington, Vermont
    Burlington, Vermont 05401, United States
  • Virginia Beach, Virginia
    Virginia Beach, Virginia 23456, United States
  • Erina, New South Wales
    Erina, New South Wales 02250, Australia
  • Woolloongabba, Queensland
    Woolloongabba, Queensland 4102, Australia
  • Parkville, Victoria
    Parkville, Victoria 3050, Australia
  • Medical center VITA1, Pleven
    Pleven, 5800, Bulgaria
  • Pleven, Bulgaria
    Pleven, 5800, Bulgaria
  • Pleven
    Pleven, 5800, Bulgaria
  • Multiprofile Hospital, Sofia
    Sofia, 1113, Bulgaria
  • Sofia
    Sofia, 1142, Bulgaria
  • Sofia
    Sofia, 1407, Bulgaria
  • DCC Neoclinic
    Sofia, 1408, Bulgaria
  • Sofia
    Sofia, 1431, Bulgaria
  • Ottawa, Ontario
    Ottawa, Ontario K1Y4E9, Canada
  • Toronto, Ontario
    Toronto, Ontario M5T 2S8, Canada
  • Poliklinika, Chocen,
    Choceň, Chocen 565 01, Czechia
  • Prague,
    Prague, 100 00, Czechia
  • Rychnov nad Kněžnou
    Rychnov nad Kněžnou, 516 01, Czechia
  • Creteil
    Créteil, Creteil 94010, France
  • Boulevard Pinel, Bron
    Bron, 69500, France
  • Grenoble cedex
    Grenoble, 38043, France
  • Nancy, France
    Nancy, 54035, France
  • Nîmes cedex
    Nîmes, 30029, France
  • Muenster
    Münster, Muenster 48149, Germany
  • Bad Homburg
    Bad Homburg, 61348, Germany
  • Duesseldorf,
    Düsseldorf, 40225, Germany
  • Haag in Oberbayern
    Haag in Oberbayern, 83527, Germany
  • Stadtroda
    Stadtroda, 07646, Germany
  • Haifa
    Haifa, 3109601, Israel
  • Petah Tiqva
    Petah Tikva, 49100, Israel
  • Ramat Gan
    Ramat Gan, 5265601, Israel
  • Tel Aviv
    Tel Aviv, 6100000, Israel
  • Milano
    Milan, 20126, Italy
  • Padova
    Padova, 35128, Italy
  • Pisa
    Pisa, 56126, Italy
  • Rome
    Rome, 00163, Italy
  • Rome
    Rome, 00179, Italy
  • Kraków
    Krakow, 30-510, Poland
  • Singua
    Warsaw, 02-777, Poland
  • Lodz
    Lodz, Łódź Voivodeship 90-640, Poland
  • Elche
    Elche, Alicante 03203, Spain
  • Barcelona
    Barcelona, 08041, Spain
  • Barcelona
    Barcelona, 08190, Spain
  • Madrid
    Madrid, 28006, Spain
  • Madrid, Spain
    Madrid, 28036, Spain
  • Madrid, Spain
    Madrid, 28922, Spain
  • Terrassa
    Terrassa, 08222, Spain
  • Valencia
    Valencia, 46026, Spain
  • Zaporiizhzhya
    Zaporizhzhya, Zaporiizhzhya 69600, Ukraine
  • Zaporozhya
    Zaporizhzhya, Zaporozhya 69035, Ukraine
  • Dnipro
    Dnipro, 49027, Ukraine
  • Kharkiv
    Kharkiv, 61068, Ukraine
09

References and documents

Publications

  • Pahwa R, Moro E, Espay AJ, Evans A, Saint-Hilaire M, Torres-Russotto D, Sanchez R, Leoni M, Duvvuri S, Combs C, Chang I, Tringali S, Boiser J, Zadikoff C, Antonini A. Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2026 May 1;83(5):452-460. doi: 10.1001/jamaneurol.2026.0590. PubMed 41860533 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jun 2024, 54 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 54 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2019
First posted
Dec 17, 2019
StartActual
Dec 13, 2019
Primary completionActual
Jun 28, 2024
CompletionActual
Jun 28, 2024
Results first posted
Jul 28, 2025
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04201093
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 17, 2019
Start date
Dec 13, 2019
Primary completion
Jun 28, 2024
Completion
Jun 28, 2024
Results posted
Jul 28, 2025
Last update
Jul 28, 2025

Study contacts

ABBVIE INC., MD
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion